Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys after hosting meetings with its management. The analyst says the discussions added to her confidence that the company’s MOR-208 will be approved in the U.S. for the treatment of refractory diffuse large b-cell lymphoma by mid-2020. Brill also maintains her view that MorphoSys is “substantially undervalued” given the “sizable commercial opportunity and the proximity to potential launch”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.